Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million , representing 12% year-over-year growth for the full year BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 14, 2025-- Quanterix Corporation (NASDAQ: QTRX), a company fueling
Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate
Award represents nation’s highest honor for technological achievement BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 6, 2025-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R.
BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 2, 2025-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43 rd Annual J.P.
